This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Preliminary Report

MORRIS SPIELBERG, M.D.

AMA Arch Intern Med. 1953;91(3):315-324.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

INTRODUCTION

DURING the past decade the trend in the therapy of rheumatoid arthritis has been toward the use of hormones. Estrogenic substances, testosterone, pregnenolone, desoxycorticosterone acetate, cortisone, and corticotropin have been used with varying degrees of success and failure. Cortisone and corticotropin are the two most recent additions to the armamentarium. However, they have many significant limitations and contraindications, as reported in the literature by Davison¹ and others. Because of these drawbacks to their universal use, the search for other active hormonal agents continues. Since 1950 I have been using placental blood serum in the therapy of rheumatoid arthritis to evaluate its antirheumatic activity, toxicity, and side-effects.

In 1938, P. S. Hench² reviewed the literature for observations of the ameliorating effect of pregnancy on rheumatoid arthritis. He found, from 1864 onward, 10 authors giving accounts of 37 cases of pregnancy among 20 women suffering with active rheumatoid arthritis. . . . [Full Text PDF of this Article]

Author Affiliations
BROOKLYN

From the Arthritis Clinic, Department of Medicine, Jewish Hospital of Brooklyn.

Footnotes
This investigation was supported in part by a grant from the Arthritis and Rheumatism Foundation Fund.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?